Chikungunya virus (CHIKV) is a mosquito-borne virus belonging to the Togaviridae family, specifically the Alphavirus genus. CHIKV is an enveloped, single-stranded RNA virus that causes severe diseases in humans and animals.
CHIKV infection leads to chikungunya fever, characterized by symptoms such as fever, rash, headache, muscle aches (myalgia), and severe joint pain. Following a post-acute infection, patients may develop severe arthritis and neurological issues, such as encephalitis, meningitis, and Guillain-Barré syndrome. Virus evolution and climate may enhance the widespread of CHIKV.
Heterodimers of the CHIKV structural proteins E1 and E2 form trimeric “viral spikes” on the surface of the viral particle. Responsibility of E2 is receptor binding, while E1 is membrane fusion. Sequence conservation of E2 among different epidemic genotypes makes it a key indicator for viral detection during the viremia phase. Neutralizing antibody development is crucial for CHIKV control.
In July 2025, chikungunya fever cases were reported in various regions of Guangdong Province. CHIKV has been reported in 119 countries and regions, and there is a potential for widespread outbreak. On July 22, the WHO issued an alert on potential large-scale outbreaks of Chikungunya, reminding countries to prepare for solutions to avoid large-scale outbreak.
In response to the new CHIKV (UVE/CHIKV/2024/RE/CNR_79903) variants, Sino Biological quickly launched recombinant E1 and E2 proteins, as well as antibodies, to support researchers in the development of vaccines, antiviral drugs, and immunodiagnostic assays.
Learn more at: https://www.sinobiological.com/research/virus/chikungunya-virus <- URL will be shortened
This is part of our ProVir viral reagent collection. Check out our catalogue for other viruses here! https://www.sinobiological.com/research/virus
